默沙东/科伦博泰 TROP2 ADC 又双叒叕启动 III 期临床试验

Insight数据库2025-05-14

5 月 13 日，ClinicalTrials 网站显示，默沙东登记了一项比较 Sac-TMT（芦康沙妥珠单抗，TROP2 ADC）联合帕博利珠单抗和卡铂/紫杉醇对比化疗联合帕博利珠单抗新辅助治疗高危、早期三阴性乳腺癌或激素受体低阳性/人表皮生长因子受体 2 阴性乳腺癌的 III 期临床研究（NCT06966700/MK-2870-032）。截图来源：ClinicalTrials 网站这是一项...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2535090653?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-14 15:02","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2535090653","market":"us","top_or_hot":-1,"title":"默沙东/科伦博泰 TROP2 ADC 又双叒叕启动 III 期临床试验","media":"Insight数据库","content":"<div>\n<p>5 月 13 日，ClinicalTrials 网站显示，默沙东登记了一项比较 Sac-TMT（芦康沙妥珠单抗，TROP2 ADC）联合帕博利珠单抗和卡铂/紫杉醇对比化疗联合帕博利珠单抗新辅助治疗高危、早期三阴性乳腺癌或激素受体低阳性/人表皮生长因子受体 2 阴性乳腺癌的 III 期临床研究（NCT06966700/MK-2870-032）。截图来源：ClinicalTrials 网站这是一项...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250514152826a6de97f2&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>默沙东/科伦博泰 TROP2 ADC 又双叒叕启动 III 期临床试验</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n默沙东/科伦博泰 TROP2 ADC 又双叒叕启动 III 期临床试验\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-14 15:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250514152826a6de97f2&s=b><strong>Insight数据库</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5 月 13 日，ClinicalTrials 网站显示，默沙东登记了一项比较 Sac-TMT（芦康沙妥珠单抗，TROP2 ADC）联合帕博利珠单抗和卡铂/紫杉醇对比化疗联合帕博利珠单抗新辅助治疗高危、早期三阴性乳腺癌或激素受体低阳性/人表皮生长因子受体 2 阴性乳腺癌的 III 期临床研究（NCT06966700/MK-2870-032）。截图来源：ClinicalTrials 网站这是一项...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250514152826a6de97f2&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756325.SGD","symbol_name":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250514152826a6de97f2&s=b","article_id":"2535090653","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250514152826a6de97f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2535090653","pubTimestamp":1747206169,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5 月 13 日，ClinicalTrials 网站显示，默沙东登记了一项比较 Sac-TMT联合帕博利珠单抗和卡铂/紫杉醇对比化疗联合帕博利珠单抗新辅助治疗高危、早期三阴性乳腺癌或激素受体低阳性/人表皮生长因子受体 2 阴性乳腺癌的 III 期临床研究。Insight 数据库显示，这是默沙东针对该药启动的第 14 项全球多中心临床试验，此前还有 13 项临床试验，涉及卵巢癌、宫颈癌、胃癌、非小细胞肺癌、子宫内膜癌等。该药首次于 2024 年 11 月获 NMPA 批准上市，用于三阴性乳腺癌的二线治疗。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","SG9999001176.USD":"United Global Healthcare Acc USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","BK4534":"瑞士信贷持仓","III":"信息服务","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","BK4516":"特朗普概念","MRK":"默沙东","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4559":"巴菲特持仓","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","ADC":"艾格里房产","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","SG9999014559.SGD":"United Income Focus Trust Dis SGD","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD"},"translate_title":"Merck/Columbotai TROP2 ADC starts phase III clinical trial again","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"III":1,"MRK":1,"ADC":1},"content_text":"5 月 13 日，ClinicalTrials 网站显示，默沙东登记了一项比较 Sac-TMT（芦康沙妥珠单抗，TROP2 ADC）联合帕博利珠单抗和卡铂/紫杉醇对比化疗联合帕博利珠单抗新辅助治疗高危、早期三阴性乳腺癌或激素受体低阳性/人表皮生长因子受体 2 阴性乳腺癌的 III 期临床研究（NCT06966700/MK-2870-032）。截图来源：ClinicalTrials 网站这是一项III 期、随机、开放标签研究，拟入组  2400 人，给药方案如下。截图来自：Insight 数据库该试验的主要终点是确定性手术时达到病理完全缓解（pCR）的参与者百分比和无事件生存期（EFS）。Insight 数据库显示，这是默沙东针对该药启动的第 14 项全球多中心临床试验，此前还有 13 项临床试验，涉及卵巢癌、宫颈癌、胃癌、非小细胞肺癌、子宫内膜癌等。值得一提的是，但从乳腺癌适应症来讲，Sac-TMT 正在逐步探索从后线拓展到一线，并且覆盖辅助和新辅助疗法。Sac-TMT 是科伦博泰研发的一款TROP2 ADC，由人源化单克隆抗体 Sacituzumab、可酶促裂解的 Linker 和新型拓扑异构酶 I 抑制剂 T030 偶联而成，药物抗体比（DAR）平均高达 7.4。该药首次于 2024 年 11 月获 NMPA 批准上市，用于三阴性乳腺癌的二线治疗。2025 年 3 月，该药在国内获批一项新适应症，用于治疗经 EGFR TKI 和含铂化疗治疗后进展的 EGFR 基因突变阳性的局部晚期或转移性非鳞状 NSCLC成人患者。2022 年 5 月，科伦博泰与默沙东签署合作协议，授予后者在大中华区以外的所有地区开发、使用、制造及商业化Sac-TMT 的独家权利。截图来源：Insight 数据库封面来源：企业 Logo","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2535090653","isCrawlerRequest":true}